Concepedia

Ravi S. Harapanhalli

RS

19

Publications

1.3K

Citations

16

H-Index

1988

Active since

Affiliations

Harvard University(Current)

University Hospital, Newark

United States Food and Drug Administration

Center for Drug Evaluation and Research

Rutgers New Jersey Medical School

Ravi S. Harapanhalli is an author at Harvard University specializing in medicine, pharmacology, and natural sciences.

Top concepts

Publications per year

1988–2008

19

Publications

19

Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma

Bhupinder Mann, John R. Johnson, Kun He et al. · Clinical Cancer Research · 2007 · 260 citations · Full text

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

Michael H. Brave, Vicki Goodman, Edvardas Kaminskas et al. · Clinical Cancer Research · 2008 · 239 citations

Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib

Maitreyee Hazarika, Xiaoping Jiang, Qi Liu et al. · Clinical Cancer Research · 2008 · 134 citations

[<sup>125</sup>I/<sup>127</sup>I]IodoHoechst 33342:  Synthesis, DNA Binding, and Biodistribution

Ravi S. Harapanhalli, Larry W. McLaughlin, Roger W. Howell et al. · Journal of Medicinal Chemistry · 1996 · 70 citations

Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies

Robert J. Lechleider, Edvardas Kaminskas, Xiaoping Jiang et al. · Clinical Cancer Research · 2008 · 66 citations · Full text

Rows per page

1–5 of 19